BioPharmSignal logoBioPharmSignal

Biotech News

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma (NAMS)NewAmsterdam PharmaEarnings

– Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed - dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK – – PREVAIL interim analysis planned for 4Q2026 with

Related news

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

SGMTSagimet Biosciences2026-05-12 11:30 EST

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

MLYSMineralys Therapeutics2026-05-06 20:05 EST

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-04-29 20:05 EST

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MLYSMineralys Therapeutics2026-03-12 20:05 EST

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

ALTAltimmune2026-05-13 11:30 EST

Altimmune Announces First Quarter 2026 Financial Results and Business Update

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

View all latest news

NewAmsterdam Pharma

Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol. Obicetrapib Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering...

Recent company news

NAMSNewAmsterdam Pharma2026-08-06 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NAMSNewAmsterdam Pharma2026-07-29 12:00 EST

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NAMSNewAmsterdam Pharma2026-07-02 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
27.67 USD
Market cap
3.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States